Search Within

Suzanne M Chanel

  1. "Center for Molecular Imaging and Biotechnology"
Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
Groups
  1. Adult Leukemia (16)
  2. Center for Hematologic Malignancies (16)
  3. Center for Molecular Imaging and Biotechnology (16)
  4. Department of Medicine (16)
  5. GSK Faculty (16)
  6. Hematologic Malignancies, Division of (16)

More Groups

People
  1. David Scheinberg (15)
  2. Joseph Jurcic (10)
  3. Peter Maslak (9)
  4. Todd Rosenblat (8)
  5. Mark Frattini (7)
  6. Tao Dao (7)

More People

Years
  1. 2018 (2)
  2. 2016 (1)
  3. 2012 (1)
  4. 2011 (2)
  5. 2010 (2)
  6. 2008 (3)

More Years

Publications
  1. Blood (6)
  2. Journal of Clinical Oncology (5)
  3. Blood Advances (1)
  4. Cancer Biotherapy and Radiopharmaceuticals (1)
  5. Clinical Cancer Research (1)
  6. Haematologica (1)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. American Society of Clinical Oncology (5)
  3. American Association for Cancer Research (1)
  4. Ferrata Storti Foundation (1)
  5. Mary Ann Liebert, Inc (1)
  6. Nature Publishing Group (1)

Results (16)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease
    Journal Article

    Maslak, P. G.; Dao, T.; Gomez, M.; Chanel, S.; Packin, J.; Korontsvit, T.; Zakhaleva, V.; Pinilla-Ibarz, J.; Berman, E.; Scheinberg, D. A.
    Leukemia (2008)

    Fulltext@MSK | Save
  • Phase I trial of the targeted alpha-particle nano-generator actinium-225 (Ac-225)-HuM195 (Anti-CD33) in acute myeloid leukemia (AML)
    Meeting Abstract

    Rosenblat, T. L.; McDevitt, M. R.; Pandit-Taskar, N.; Carrasquillo, J. A.; Chanel, S.; Frattini, M. G.; Larson, S. M.; Scheinberg, D. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Pilot trial of a synthetic breakpoint peptide vaccine in patients with chronic myeloid leukemia (CML) and minimal disease
    Meeting Abstract

    Maslak, P. G.; Dao, T.; Gupta, S.; Gomez, M.; Chanel, S.; Korontsvit, T.; Zakhaleva, V.; Ashraf, S.; Berman, E.; Scheinberg, D.
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Alpha-particle immunotherapy for acute myeloid leukemia (AML) with bismuth-213 and actinium-225
    Meeting Abstract

    Jurcic, J. G.; McDevitt, M. R.; Pandit-Taskar, N.; Divgi, C. R.; Finn, R. D.; Sgouros, G.; Apostalidis, C.; Chanel, S.; Larson, S. M.; Scheinberg, D. A.
    Cancer Biotherapy and Radiopharmaceuticals (2006)

    Fulltext@MSK | Save
  • Induction with combined modality therapy followed by immunomodulated post remission therapy for newly diagnosed acute myeloid leukemia (AML)
    Meeting Abstract

    Gupta, S.; Weiss, M. A.; Jurcic, J. G.; Chanel, S.; Wilson, B. A.; Biederman, E.; Berman, E.; Scheinberg, D. A.; Maslak, P. G.
    Blood (2005)

    Fulltext@MSK | Save
  • Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
    Journal Article

    Camacho, L. H.; Soignet, S. L.; Chanel, S.; Ho, R.; Heller, G.; Scheinberg, D. A.; Ellison, R.; Warrell, R. P.
    Journal of Clinical Oncology (2000)

    Fulltext@MSK | Save